Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 8/20 | 0.54 |
| ▸ | CA2 | P00918 | 8/20 | 0.54 |
| ▸ | CA9 | Q16790 | 8/20 | 0.54 |
| ▸ | CA1 | P00915 | 6/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 10/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6726154 | 0.85 | PTGS2 (0.53) | CA12CA2CA9CA1PTGS2 | |
| SCHEMBL6725794 | 0.85 | CA2 (0.68) | CA12CA2CA9CA1PTGS2 | |
| SCHEMBL28129527 | 0.85 | CA2 (0.75) | CA12CA2CA9CA1PTGS2 | |
| SCHEMBL6725866 | 0.85 | CA2 (0.57) | CA12CA2CA9CA1PTGS2 | |
| SCHEMBL6723983 | 0.85 | CA2 (0.57) | CA12CA2CA9CA1PTGS2 | |
| SCHEMBL8770544 | 0.84 | MAOA (0.59) | CA12CA2CA9CA1PTGS2 | |
| SCHEMBL6721496 | 0.83 | PTGS2 (0.66) | CA12CA2CA9CA1PTGS2 | |
| SCHEMBL6723830 | 0.82 | KIF11 (0.54) | CA12CA2CA9CA1PTGS2 | |
| SCHEMBL6726452 | 0.81 | CA9 (0.56) | CA12CA2CA9CA1PTGS2 | |
| SCHEMBL6724390 | 0.81 | CA2 (0.47) | CA12CA2CA9CA1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040158074-A1 | Substituted biphenyl compounds for the treatment of inflammation | G.D. SEARLE & CO. | 2004-08-12 | — | — | US | disclosed |
| EP-0794942-B1 | SUBSTITUTED BIPHENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2000-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040158074-A1 | Substituted biphenyl compounds for the treatment of inflammation | AHR, ARNT, GPBAR1 | CA12 3828/4885CA2 2743/4885CA9 2885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.